Craniopharyngioma: Complications and Treatment

Overview

• Adamantinomatous (90%): more common in children; mixed solid/cystic with calcifications; CTNNB1 (beta-catenin) mutations (~94%)
• Papillary (10%): predominant in adults; mostly solid, rarely calcified; BRAF V600E mutations (~95%)

Imaging

Complications

Tumor-Related Complications

Post-Treatment Complications

• Complete panhypopituitarism and diabetes insipidus
• Severe hypothalamic obesity (damage to thirst, temperature, and appetite regulatory centers)
• Permanent neuroendocrine deficits requiring lifelong hormone replacement

• Cognitive and endocrine deficits
• Optic neuropathy
• Secondary malignancies
• Vascular injury - moyamoya disease

Treatment

1. Surgery (Primary Treatment)

• Transsphenoidal (preferred when hypothalamus is not involved; also for subdiaphragmatic tumors)
• Transcranial (subfrontal or pterional) for larger/suprasellar extension
• Endoscopic endonasal surgery (EES) - increasingly used; can be employed regardless of size/location except purely intraventricular tumors

• After total resection: ~30%
• After subtotal resection: ~57%
• After subtotal resection + radiation: ~30%

2. Radiation Therapy

• External beam radiotherapy (EBRT): Extends progression-free survival (PFS) after incomplete resection; used as primary treatment for unresectable or recurrent tumors
• Stereotactic radiosurgery (e.g., Gamma Knife): Used for small residual or recurrent disease
• Intracavitary irradiation: ³²P or ⁹⁰Y instilled into cystic components after stereotactic aspiration; suitable for purely cystic or mixed tumors

3. Intracystic Therapy (for Cystic Craniopharyngioma)

• Bleomycin (sclerosing agent) - risk of severe neurotoxicity if the cyst wall leaks into CSF
• Interferon-alpha - subcutaneous (short-acting or pegylated) or intracystic injection; shows promising results in delaying need for radiotherapy
• ³²P or ⁹⁰Y (radioactive colloids)

4. Targeted (Molecular) Therapy

• Papillary subtype (BRAF V600E): BRAF inhibitors (vemurafenib/dabrafenib) + MEK inhibitors have shown success in case reports and small series. A Phase II trial of combined MEK/BRAF inhibition is ongoing.
• Adamantinomatous subtype (CTNNB1/beta-catenin): Drugs targeting the Wnt/beta-catenin pathway are still under development.

5. Hormone Replacement

• GH, thyroid hormone, cortisol (ACTH axis), sex steroids, vasopressin (DI)
• Monitoring and treatment of hypothalamic obesity

Prognosis

Post-Craniotomy Hyponatremia After Hypernatremia in Craniopharyngioma

The Triphasic Response: Pathophysiology

Phase 1 - Diabetes Insipidus (Hypernatremia) - Hours to Days

• Mechanism: Axon shock following stalk transection. The severed axons cannot transmit signals from the hypothalamus to the posterior pituitary, so AVP secretion ceases.
• Result: Massive polyuria (hypotonic urine), hypernatremia, hypernatremia, rising serum osmolality.
• Duration: Several hours to a few days.

Phase 2 - SIADH (Hyponatremia) - Days 2 to 14

• Mechanism: The disconnected posterior pituitary gland (and the remaining severed axon terminals) undergoes Wallerian-type degeneration. As the axon terminals die, they dump all stored AVP uncontrollably into the bloodstream. This AVP release is completely autonomous - it is not regulated by osmolality or volume status.
• Result: Concentrated urine, free water retention, dilutional hyponatremia.
• Critical trap: Overly aggressive fluid administration during Phase 1 (to treat DI/hypernatremia) does NOT suppress this uncontrolled AVP release and can worsen the degree of dilutional hyponatremia in Phase 2.
• Duration: 2 to 14 days (until posterior pituitary AVP stores are depleted).

Phase 3 - Return of Permanent DI - After Day 10-14

• Mechanism: Once all stored AVP in the degenerating posterior pituitary is exhausted, DI returns - this time permanently, because >80-90% of the hypothalamic AVP neuronal cell bodies have undergone retrograde degeneration.
• Result: Polyuria resumes, permanent diabetes insipidus requiring lifelong desmopressin.

"Overly aggressive administration of fluids during the second phase does not suppress the uncontrolled vasopressin release from the damaged neurohypophysis and can lead to hyponatremia." - Goldman-Cecil Medicine

Isolated Second Phase (Without Phase 1 DI)

Clinical Data in Pediatric Craniopharyngioma

• 65.4% (17/26) had the full triphasic pattern: initial DI followed by hyponatremia days later
• 30.8% (8/26) had isolated persistent DI
• Triphasic response was significantly associated with higher Puget MRI classification (grades 1 and 2, indicating greater hypothalamic involvement)
• Dysnatremia was described as the most common and difficult-to-manage immediate post-operative complication

Differential Diagnosis of Post-Craniotomy Hyponatremia

"SIADH is treated by free-water restriction, whereas cerebral salt wasting is treated with volume repletion and sodium administration... Urine electrolyte analysis is not discriminative, as urine sodium is high in both disorders." - Barash's Clinical Anesthesia

Management of Phase 2 Hyponatremia

During the Transition (Phase 1 → Phase 2)

• Watch for abrupt cessation of polyuria - this signals the onset of Phase 2 AVP release
• Reduce or stop free water and hypotonic fluid administration immediately
• Do not reflexively give more fluids because urine output drops

Treating the Hyponatremia

1. Fluid restriction is the mainstay (euvolemic/hypervolemic SIADH)
2. Avoid over-correction - correction of hyponatremia must not exceed 8-10 mEq/L per 24 hours to prevent osmotic demyelination syndrome (central pontine myelinolysis), especially if hyponatremia is chronic or symptomatic
3. For severe symptomatic hyponatremia (seizures, altered consciousness): hypertonic saline (3% NaCl) can be given cautiously at controlled rates
4. Rule out concurrent adrenal insufficiency (common post-craniopharyngioma surgery given panhypopituitarism) - glucocorticoid deficiency independently causes hyponatremia and should be corrected with hydrocortisone

Monitoring

• Serum sodium every 4-6 hours in the acute post-operative phase
• Strict urine output monitoring - the shift from high to low output marks the phase transition
• After Day 14, anticipate return of DI and resume desmopressin

Avoiding the Trap

Summary Timeline

Surgery
   |
   ├── Hours 0–48: Phase 1 - DI → HYPERNATREMIA (polyuria, high serum Na+)
   |       ↓ Axon shock, no AVP release
   |
   ├── Days 2–14: Phase 2 - SIADH → HYPONATREMIA (oliguria, low serum Na+)
   |       ↓ Uncontrolled AVP dump from degenerating posterior pituitary
   |       ↓ *** Fluid restriction; avoid overcorrection ***
   |
   └── After Day 10–14: Phase 3 - Permanent DI returns
           ↓ AVP stores exhausted; retrograde neuronal degeneration
           ↓ Lifelong desmopressin required

How Hydrocortisone Corrects Hyponatremia Post-Craniotomy for Craniopharyngioma

Why Cortisol Deficiency Causes Hyponatremia

Mechanism 1 - Loss of Negative Feedback on AVP (the central mechanism)

• CRH neurons in the hypothalamic paraventricular nucleus co-secrete both CRH and AVP to stimulate ACTH release from the anterior pituitary
• Cortisol normally exerts negative feedback at both the hypothalamic and pituitary levels - it suppresses CRH release and reduces pituitary sensitivity to CRH, thereby dampening co-secreted AVP
• When cortisol is absent (ACTH deficiency after craniopharyngioma surgery), this feedback brake is lost
• The CRH/AVP co-secreting neurons fire unchecked → plasma AVP rises autonomously
• The elevated AVP acts on V2 receptors in the renal collecting duct → water retention → dilutional hyponatremia

"The deficiency of cortisol leads to failure to suppress vasopressin levels, and the hyponatremia resembles SIADH rather than classic primary adrenal insufficiency." - Goldman-Cecil Medicine

"CRH and vasopressin have synergistic effects on the release of ACTH... In a feedback loop, cortisol decreases ACTH secretion at both the hypothalamic and the pituitary levels." - Goldman-Cecil Medicine

• There is no urinary sodium wasting (unlike primary Addison's disease)
• Volume status is euvolemic or mildly expanded
• The picture is indistinguishable from SIADH on lab testing - urine sodium is high, urine osmolality is high, serum osmolality is low

Mechanism 2 - Direct Renal Effect on Free Water Excretion

• Cortisol promotes maximal diluting capacity in the ascending limb of the loop of Henle and the collecting duct
• In its absence, the kidney cannot fully dilute urine even when AVP is suppressed - the "solute-free water clearance" (CH₂O) falls
• Glucocorticoid deficiency can prevent maximal urine dilution through a direct tubular mechanism, independent of AVP levels

"Glucocorticoid deficiency and SIADH can be especially difficult to distinguish, because either primary or secondary hypocortisolism can cause elevated plasma AVP levels and, in addition, can have direct kidney effects to prevent maximal urine dilution." - NKF Primer on Kidney Diseases

Mechanism 3 - Cardiovascular/Hemodynamic (secondary)

• Cortisol is required to maintain vascular tone and cardiac output
• Cortisol deficiency reduces effective arterial blood volume (EABV) → baroreceptor-mediated non-osmotic AVP release (a volume stimulus for AVP secretion)
• This adds a second, hemodynamically-driven AVP stimulus on top of the hypothalamic feedback mechanism
• Hydrocortisone restores vascular responsiveness to catecholamines, improves cardiac output, and removes this non-osmotic AVP drive

How Hydrocortisone Corrects Hyponatremia: Summary of Actions

CORTISOL DEFICIENCY (post-craniopharyngioma, ACTH loss)
              │
    ┌─────────┴──────────────────────────────┐
    │                                        │
    ▼                                        ▼
Loss of hypothalamic              Reduced cardiac output /
negative feedback                 vascular tone
    │                                        │
    ▼                                        ▼
Unregulated CRH/AVP           Non-osmotic AVP release
co-secretion                  (baroreceptor-mediated)
    │                                        │
    └──────────────┬─────────────────────────┘
                   ▼
          ↑ Plasma AVP
                   │
                   ▼
       V2 receptor in collecting duct
                   │
                   ▼
       ↑ AQP2 water channels → water retention
                   │
                   ▼
         DILUTIONAL HYPONATREMIA

══════════════ HYDROCORTISONE ══════════════

    Restores hypothalamic        Restores vascular tone
    negative feedback      +     and cardiac output
         │                            │
         ▼                            ▼
    Suppresses CRH/AVP          Removes baroreceptor
    co-secretion                AVP stimulus
         │                            │
         └──────────┬─────────────────┘
                    ▼
           ↓ Plasma AVP → aquaresis
                    ▼
           Sodium rises (dilution corrects)

Why This Matters Specifically Post-Craniopharyngioma

Practical implication

1. The lab picture is identical to SIADH (euvolemia, high urine Na, high urine osmolality, low serum Na)
2. Water restriction alone will not work if cortisol deficiency is the driver
3. Hydrocortisone replacement is specific, rapidly effective, and diagnostically confirmatory - sodium will rise within 24-48 hours if cortisol deficiency was the cause

"No patient with chronic hyponatremia should be diagnosed as having SIADH without a thorough evaluation of adrenal function." - NKF Primer on Kidney Diseases